Sophie Duraffour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sophie Duraffour has a total of 248 co-authors. Here are the top co-authors by number of shared publications:
- Stephan Günther
Department of Virology, Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany
12 shared publications - Giuditta Annibaldis
Department of Virology, Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany
6 shared publications - Sanaba Boumbaly
Center for Virology Research - Laboratory for Viral Hemorrhagic Fevers in Guinea (CRV-LFHVG), Conakry, Guinea
6 shared publications Fara Raymond Koundouno
Laboratory for Viral Hemorrhagic Fevers of Guéckédou (LFHV-GKD), Prefectural Health Department of Guéckédou, Guéckédou, Guinea
5 shared publicationsJulia Hinzmann
Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
5 shared publicationsKékoura Ifono
Laboratory for Viral Hemorrhagic Fevers of Guéckédou (LFHV-GKD), Prefectural Health Department of Guéckédou, Guéckédou, Guinea
5 shared publications
Latest Publications
- Open Access
Seroprevalence of viral hemorrhagic fevers and arboviral infections among febrile patients in Forest Guinea
Between 2017 and 2024, routine diagnostics surveillance in Guinea detected several confirmed viral hemorrhagic fever (VHF) cases among febrile patients. To assess exposure to Lassa virus and other viral pathogens, we conducted a retrospective cross-sectional seroprevalence study in Forest Guinea (Guéckédou and N’Zérékoré). Lassa virus seroprevalence was 56.0% in the Guéckédou study group and 29.8% in the N’Zérékoré study group. Seropositivity increased with age in both study groups, suggesting cumulative exposure. Samples from Guéckédou laboratory were also tested for other pathogens, and antibodies against Marburg virus (5.8%), Zika virus (5.4%) and Crimean-Congo haemorrhagic fever virus (1.2%) were detected.
Open AccessSeroprevalence of viral hemorrhagic fevers and arboviral infections among febrile patients in Forest Guinea
Between 2017 and 2024, routine diagnostics surveillance in Guinea detected several confirmed viral hemorrhagic fever (VHF) cases among febrile patients. To assess exposure to Lassa virus and other viral pathogens, we conducted a retrospective cross-sectional seroprevalence study in Forest Guinea (Guéckédou and N’Zérékoré). Lassa virus seroprevalence was 56.0% in the Guéckédou study group and 29.8% in the N’Zérékoré study group. Seropositivity increased with age in both study groups, suggesting cumulative exposure. Samples from Guéckédou laboratory were also tested for other pathogens, and antibodies against Marburg virus (5.8%), Zika virus (5.4%) and Crimean-Congo haemorrhagic fever virus (1.2%) were detected.
- Open Access
- 15 May 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 1-11
Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Lassa fever (LF) is a viral hemorrhagic fever endemic to West Africa, with high case fatality in hospitalized patients and limited treatment options, including ribavirin. Preclinical evidence suggests high-dose favipiravir is a promising antiviral treatment alternative. We conducted a randomized controlled open-label phase 2 clinical trial at two reference hospitals in Nigeria to evaluate favipiravir in the treatment of LF. Primary endpoints were the description of classic pharmacokinetic parameters (maximum plasma concentration, time to reach maximum plasma concentration, area under the curve (AUC), half-life and volume of distribution) as well as the safety and tolerability of favipiravir compared with ribavirin in the treatment of acute LF. Hospitalized adult patients with mild-to-moderate RT-PCR-confirmed LF were eligible to participate. In total, 41 patients were randomized (ribavirin n = 21; favipiravir n = 20), and 36 completed the 10-day follow-up period. A total of 19 (46.3%) participants were female, and the median age was 37 years. The primary endpoints were met. Pharmacokinetic analysis of favipiravir in a one-compartment model indicated reliable exposure with maximum plasma concentration of 50.9 (IQR 42.1 to 75.1) mg l−1 in steady state, half-life of 10.9 (IQR 8.2 to 17.1) h and AUC (0–240 h) of 9,275 (IQR 7,139.4 to 15,794.8) mg l−1 h−1. The 30 drug-related treatment-emergent adverse events were evenly distributed between the treatment arms; 16 (53.5%) events occurred in the favipiravir group, and none of these were classified as severe or serious. Anemia was the most frequently observed adverse event in the ribavirin arm and vomiting in the favipiravir arm. All study participants survived and were successfully discharged from the isolation ward. This trial indicates favipiravir’s potential as a safe and well-tolerated alternative treatment regimen for LF and pharmacokinetic data suggest an optimized favipiravir regimen for future clinical evaluation. Clinicaltrials.gov: NCT04907682.
- 15 May 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 1-11
Open AccessFavipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Lassa fever (LF) is a viral hemorrhagic fever endemic to West Africa, with high case fatality in hospitalized patients and limited treatment options, including ribavirin. Preclinical evidence suggests high-dose favipiravir is a promising antiviral treatment alternative. We conducted a randomized controlled open-label phase 2 clinical trial at two reference hospitals in Nigeria to evaluate favipiravir in the treatment of LF. Primary endpoints were the description of classic pharmacokinetic parameters (maximum plasma concentration, time to reach maximum plasma concentration, area under the curve (AUC), half-life and volume of distribution) as well as the safety and tolerability of favipiravir compared with ribavirin in the treatment of acute LF. Hospitalized adult patients with mild-to-moderate RT-PCR-confirmed LF were eligible to participate. In total, 41 patients were randomized (ribavirin n = 21; favipiravir n = 20), and 36 completed the 10-day follow-up period. A total of 19 (46.3%) participants were female, and the median age was 37 years. The primary endpoints were met. Pharmacokinetic analysis of favipiravir in a one-compartment model indicated reliable exposure with maximum plasma concentration of 50.9 (IQR 42.1 to 75.1) mg l−1 in steady state, half-life of 10.9 (IQR 8.2 to 17.1) h and AUC (0–240 h) of 9,275 (IQR 7,139.4 to 15,794.8) mg l−1 h−1. The 30 drug-related treatment-emergent adverse events were evenly distributed between the treatment arms; 16 (53.5%) events occurred in the favipiravir group, and none of these were classified as severe or serious. Anemia was the most frequently observed adverse event in the ribavirin arm and vomiting in the favipiravir arm. All study participants survived and were successfully discharged from the isolation ward. This trial indicates favipiravir’s potential as a safe and well-tolerated alternative treatment regimen for LF and pharmacokinetic data suggest an optimized favipiravir regimen for future clinical evaluation. Clinicaltrials.gov: NCT04907682.
- Open Access
- 23 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (2) , 189-197
Nosocomial Outbreak of Lassa Fever in Conakry, Guinea, 2022
Background: Lassa fever is endemic in Guinea, with high seroprevalence in the forest region. However, clinical cases have been only anecdotally reported. In August 2022, a nosocomial outbreak occurred at a private clinic in the capital, Conakry, an area previously considered low risk. Methods: Suspected cases were confirmed by real-time reverse-transcription polymerase chain reaction within 24 hours. Viremia was monitored during hospitalization, and whole-genome sequencing was performed in-country within 13 days of outbreak detection. Outbreak investigation involved rodent testing in the home village of the suspected primary case. Results: Six cases were laboratory-confirmed, 5 of which were healthcare workers of the clinic. The case fatality rate was 16.7%. Viral RNA remained detectable in blood of survivors for a median of 26 days (interquartile range, 24–41 days) post–disease onset. Epidemiological investigations identified a suspected primary case, who had died of a febrile disease compatible with Lassa fever, had contact with all secondary cases, and had a travel history from Kissidougou area. Three near-complete and 1 partial Lassa virus genomes were recovered from the secondary cases, which phylogenetically clustered with genomes from central Guinea. Consistent with a common transmission source, the 4 genomes were almost identical. Rodent testing revealed a new reservoir area in eastern-central Guinea. Conclusions: This outbreak highlights the vulnerability of healthcare settings in low-prevalence areas of West Africa to nosocomial Lassa virus transmission due to human mobility. Facilitated by capacity-building programs for viral hemorrhagic fevers, rapid diagnosis, genomic analysis, and ecological assessment enabled an efficient outbreak response and control.
- 23 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (2) , 189-197
Open AccessNosocomial Outbreak of Lassa Fever in Conakry, Guinea, 2022
Background: Lassa fever is endemic in Guinea, with high seroprevalence in the forest region. However, clinical cases have been only anecdotally reported. In August 2022, a nosocomial outbreak occurred at a private clinic in the capital, Conakry, an area previously considered low risk. Methods: Suspected cases were confirmed by real-time reverse-transcription polymerase chain reaction within 24 hours. Viremia was monitored during hospitalization, and whole-genome sequencing was performed in-country within 13 days of outbreak detection. Outbreak investigation involved rodent testing in the home village of the suspected primary case. Results: Six cases were laboratory-confirmed, 5 of which were healthcare workers of the clinic. The case fatality rate was 16.7%. Viral RNA remained detectable in blood of survivors for a median of 26 days (interquartile range, 24–41 days) post–disease onset. Epidemiological investigations identified a suspected primary case, who had died of a febrile disease compatible with Lassa fever, had contact with all secondary cases, and had a travel history from Kissidougou area. Three near-complete and 1 partial Lassa virus genomes were recovered from the secondary cases, which phylogenetically clustered with genomes from central Guinea. Consistent with a common transmission source, the 4 genomes were almost identical. Rodent testing revealed a new reservoir area in eastern-central Guinea. Conclusions: This outbreak highlights the vulnerability of healthcare settings in low-prevalence areas of West Africa to nosocomial Lassa virus transmission due to human mobility. Facilitated by capacity-building programs for viral hemorrhagic fevers, rapid diagnosis, genomic analysis, and ecological assessment enabled an efficient outbreak response and control.
- Open Access
Genomic surveillance of Lassa virus in Guinea through in-country sequencing
Strengthening in-country sequencing capacity generated 28 Lassa virus genomes from human clinical cases, expanding our knowledge of Lassa fever in Guinea. Phylogeographic analysis revealed cross-border exchange between Liberia and the N’Zérékoré region, and a Sierra Leone introduction into the Guéckédou area. Enhanced genomic surveillance is crucial to guide future public health actions.
Open AccessGenomic surveillance of Lassa virus in Guinea through in-country sequencing
Strengthening in-country sequencing capacity generated 28 Lassa virus genomes from human clinical cases, expanding our knowledge of Lassa fever in Guinea. Phylogeographic analysis revealed cross-border exchange between Liberia and the N’Zérékoré region, and a Sierra Leone introduction into the Guéckédou area. Enhanced genomic surveillance is crucial to guide future public health actions.
- Open Access
Emergence of mpox in Guinea: sporadic clade IIa cases and a clade IIb upsurge
Background: Mpox virus (MPXV) has caused recurrent outbreaks in West Africa. However, Guinea had not previously reported laboratory-confirmed cases or MPXV genomic data. Methods: Suspected cases were identified in the N’Zérékoré region as well as in the Conakry (Sept 2024– Dec 2025) and confirmed by real-time PCR in regional and central laboratories, respectively. Whole-genome sequencing using nanopore technology was performed in-country, followed by phylogenetic and time-scaled evolutionary analyses. Findings: The first mpox case was clinically diagnosed in September 2024 in the N’Zérékoré region and laboratory-confirmed by the prefectural laboratory in Guéckédou. In total, seven cases were confirmed in Forest Guinea, of which five complete or almost complete MPXV genomes were recovered. All belonged to MPXV clade IIa. Genomic divergence, ancestral dating, and low APOBEC3-associated mutation frequencies were consistent with multiple independent zoonotic spillover events. In June 2025, one of the first mpox cases of an unfolding outbreak was confirmed in Conakry. Whole genome sequencing revealed MPXV clade IIb lineage G.1. By December 2025, the number of laboratory-confirmed mpox cases nationwide increased to 2,151. A total of nine outbreak strains were sequenced, all belonging to Clade IIb. The genomes clustered with contemporaneous genomes from Sierra Leone and showed high APOBEC3-associated mutation frequencies, suggesting sustained human-to-human transmission in the region. Interpretation: These data demonstrate simultaneous circulation of MPXV clade IIa and IIb strains in Guinea, likely resulting from zoonotic spillover and human-to-human transmission, respectively. Decentralised diagnostics and in-country sequencing facilitated rapid case confirmation and genomic surveillance, highlighting the importance of these critical capacities for outbreak preparedness and response. Funding: German Federal Ministry of Health and the German Center for Infection Research (DZIF).
Open AccessEmergence of mpox in Guinea: sporadic clade IIa cases and a clade IIb upsurge
Background: Mpox virus (MPXV) has caused recurrent outbreaks in West Africa. However, Guinea had not previously reported laboratory-confirmed cases or MPXV genomic data. Methods: Suspected cases were identified in the N’Zérékoré region as well as in the Conakry (Sept 2024– Dec 2025) and confirmed by real-time PCR in regional and central laboratories, respectively. Whole-genome sequencing using nanopore technology was performed in-country, followed by phylogenetic and time-scaled evolutionary analyses. Findings: The first mpox case was clinically diagnosed in September 2024 in the N’Zérékoré region and laboratory-confirmed by the prefectural laboratory in Guéckédou. In total, seven cases were confirmed in Forest Guinea, of which five complete or almost complete MPXV genomes were recovered. All belonged to MPXV clade IIa. Genomic divergence, ancestral dating, and low APOBEC3-associated mutation frequencies were consistent with multiple independent zoonotic spillover events. In June 2025, one of the first mpox cases of an unfolding outbreak was confirmed in Conakry. Whole genome sequencing revealed MPXV clade IIb lineage G.1. By December 2025, the number of laboratory-confirmed mpox cases nationwide increased to 2,151. A total of nine outbreak strains were sequenced, all belonging to Clade IIb. The genomes clustered with contemporaneous genomes from Sierra Leone and showed high APOBEC3-associated mutation frequencies, suggesting sustained human-to-human transmission in the region. Interpretation: These data demonstrate simultaneous circulation of MPXV clade IIa and IIb strains in Guinea, likely resulting from zoonotic spillover and human-to-human transmission, respectively. Decentralised diagnostics and in-country sequencing facilitated rapid case confirmation and genomic surveillance, highlighting the importance of these critical capacities for outbreak preparedness and response. Funding: German Federal Ministry of Health and the German Center for Infection Research (DZIF).
- Open Access
Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection
Viral hemorrhagic fevers (VHFs), including filoviruses, Lassa virus, yellow fever virus and dengue virus, remain a major public health threat in resource-limited settings. The 2014–2016 Ebola epidemic exposed critical gaps in laboratory preparedness and diagnostic capacity in most-at-risk countries, including Guinea. In order to implement sustainable in-country laboratory capacity for early detection and rapid response to VHF outbreaks, a decentralized diagnostics laboratory strengthening program started in the forested region of Guinea in Guéckédou (2017) and N’Zérékoré (2021). Between 2017 and 2024, a total of 4683 samples from suspected VHF cases were tested across the two laboratories. Of those, 47 (1%) were identified as positive for VHFs by molecular testing, including the 2021 Ebola virus disease resurgence and Marburg virus disease emergence samples, for which the laboratories supported rapid outbreak detection and case management. Notably, between 2020 and 2024, 30 Lassa fever cases were laboratory-confirmed with a case fatality rate of 67.9%. Of those, 66.7% were men, with 50.0% and 27.6% of the cases originating from the Guéckédou and N’Zérékoré prefecture, respectively. Prior to this program, Lassa fever detection in Guinea remained anecdotic. One case of yellow fever and one of dengue were also identified by molecular assays. The establishment of locally embedded laboratory infrastructure enhanced VHFs preparedness, surveillance, and response in Guinea. Beyond improving understanding of Lassa fever epidemiology, this program highlights the value of sustained laboratory capacity for early detection and health system resilience in VHF-endemic settings.
Open AccessStrengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection
Viral hemorrhagic fevers (VHFs), including filoviruses, Lassa virus, yellow fever virus and dengue virus, remain a major public health threat in resource-limited settings. The 2014–2016 Ebola epidemic exposed critical gaps in laboratory preparedness and diagnostic capacity in most-at-risk countries, including Guinea. In order to implement sustainable in-country laboratory capacity for early detection and rapid response to VHF outbreaks, a decentralized diagnostics laboratory strengthening program started in the forested region of Guinea in Guéckédou (2017) and N’Zérékoré (2021). Between 2017 and 2024, a total of 4683 samples from suspected VHF cases were tested across the two laboratories. Of those, 47 (1%) were identified as positive for VHFs by molecular testing, including the 2021 Ebola virus disease resurgence and Marburg virus disease emergence samples, for which the laboratories supported rapid outbreak detection and case management. Notably, between 2020 and 2024, 30 Lassa fever cases were laboratory-confirmed with a case fatality rate of 67.9%. Of those, 66.7% were men, with 50.0% and 27.6% of the cases originating from the Guéckédou and N’Zérékoré prefecture, respectively. Prior to this program, Lassa fever detection in Guinea remained anecdotic. One case of yellow fever and one of dengue were also identified by molecular assays. The establishment of locally embedded laboratory infrastructure enhanced VHFs preparedness, surveillance, and response in Guinea. Beyond improving understanding of Lassa fever epidemiology, this program highlights the value of sustained laboratory capacity for early detection and health system resilience in VHF-endemic settings.
- Open Access
- 29 December 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (1)
ViMOP: a user-friendly and field-applicable pipeline for untargeted viral genome nanopore sequencing
Motivation: Untargeted, also known as metagenomic, nanopore sequencing is a powerful tool for virus genomic surveillance, particularly in resource-limited settings and when paired with the portability of the MinION device (Oxford Nanopore Technologies, ONT). However, a major bottleneck for global access is the absence of a user-friendly software capable of efficiently analyzing untargeted nanopore sequencing data to generate high-quality consensus genomes. Results: We share ViMOP, a pipeline built on our long-term experience in nanopore field sequencing. The pipeline emphasizes field user-friendliness, flexibility and versatility to analyze reads generated directly from human clinical samples. The software assembles de novo contigs, matches contigs to known viral references and uses them to assemble consensus genomes. Executed with a single Nextflow command or via the EPI2ME Desktop interface (ONT), results are summarized in an HTML report. ViMOP, through its user-centered design, lowers the barrier to high-quality virus genome reconstruction and advances capacity for genomic surveillance. Availability and implementation: ViMOP is freely available for non-commercial use (https://github.com/opr-group-bnitm/vimop and https://zenodo.org/records/17913089), along with the associated database (https://zenodo.org/records/17652512), the scripts used to generate it (https://zenodo.org/records/17632662) and benchmarking code (https://zenodo.org/records/17633185).
- 29 December 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (1)
Open AccessViMOP: a user-friendly and field-applicable pipeline for untargeted viral genome nanopore sequencing
Motivation: Untargeted, also known as metagenomic, nanopore sequencing is a powerful tool for virus genomic surveillance, particularly in resource-limited settings and when paired with the portability of the MinION device (Oxford Nanopore Technologies, ONT). However, a major bottleneck for global access is the absence of a user-friendly software capable of efficiently analyzing untargeted nanopore sequencing data to generate high-quality consensus genomes. Results: We share ViMOP, a pipeline built on our long-term experience in nanopore field sequencing. The pipeline emphasizes field user-friendliness, flexibility and versatility to analyze reads generated directly from human clinical samples. The software assembles de novo contigs, matches contigs to known viral references and uses them to assemble consensus genomes. Executed with a single Nextflow command or via the EPI2ME Desktop interface (ONT), results are summarized in an HTML report. ViMOP, through its user-centered design, lowers the barrier to high-quality virus genome reconstruction and advances capacity for genomic surveillance. Availability and implementation: ViMOP is freely available for non-commercial use (https://github.com/opr-group-bnitm/vimop and https://zenodo.org/records/17913089), along with the associated database (https://zenodo.org/records/17652512), the scripts used to generate it (https://zenodo.org/records/17632662) and benchmarking code (https://zenodo.org/records/17633185).
- Open Access
- 25 December 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (12) , e022083
Integrating mobile laboratories into global health security: advancing collaboration through GOARN-DiSC
- 25 December 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (12) , e022083
Open AccessIntegrating mobile laboratories into global health security: advancing collaboration through GOARN-DiSC
- Open Access
- 4 July 2023
- Published by Nepal Journals Online (JOL) in International Journal of Occupational Safety and Health
- Vol. 13 (3) , 272-281
Lassa Fever Infection among Healthcare Workers during the 2018 Outbreak in Nigeria
Introduction: Healthcare workers (HCWs) are potentially exposed to infection during viral hemorrhagic fever outbreaks. In the wake of 2018, Nigeria experienced an unprecedented surge in cases of Lassa fever (LF), which affected HCWs. To guide infection prevention and control (IPC) strategies in similar settings, we characterize HCWs' infection and describe the gaps in IPC standards and practices during the outbreak. Methods: Data was collected using a structured questionnaire, interview, and review of case notes of 21 HCW with laboratory-confirmed Lassa fever who were treated at the Irrua Specialist Teaching Hospital (ISTH) Irrua and the Alex-Ekwemen Federal Teaching Hospital, Abakaliki (AEFETHA), between 1st January and 27th May 2018. Information collected was the patients' socio-demographic characteristics, date of potential exposure and onset of illness, nature, and type of exposure, clinical features, outcome, use of personal protective equipment (PPE), and personnel IPC training and were analyzed using descriptive statistics with Microsoft Excel. Results: The study included 21 HCWs, and 12 (57.14%) were doctors. The case fatality rate was 23%. Nearly two-thirds (62%) of the HCWs could describe a likely procedure leading to their exposure and infection. Among 13 HCWs, 85% had multiple blood and body fluids exposure, while 15% had needle stick injury or scalpel cut. About one-fifth of the participants had received some IPC training. Conclusion: Limited IPC adherence and inappropriate risk assessment were identified as factors leading to Lassa fever exposure and infection among HCWs. There is an urgent need to provide IPC training for all HCWs and to ensure an adequate supply of IPC materials to all healthcare facilities as part of emergency preparedness, especially in LF endemic areas.
- 4 July 2023
- Published by Nepal Journals Online (JOL) in International Journal of Occupational Safety and Health
- Vol. 13 (3) , 272-281
Open AccessLassa Fever Infection among Healthcare Workers during the 2018 Outbreak in Nigeria
Introduction: Healthcare workers (HCWs) are potentially exposed to infection during viral hemorrhagic fever outbreaks. In the wake of 2018, Nigeria experienced an unprecedented surge in cases of Lassa fever (LF), which affected HCWs. To guide infection prevention and control (IPC) strategies in similar settings, we characterize HCWs' infection and describe the gaps in IPC standards and practices during the outbreak. Methods: Data was collected using a structured questionnaire, interview, and review of case notes of 21 HCW with laboratory-confirmed Lassa fever who were treated at the Irrua Specialist Teaching Hospital (ISTH) Irrua and the Alex-Ekwemen Federal Teaching Hospital, Abakaliki (AEFETHA), between 1st January and 27th May 2018. Information collected was the patients' socio-demographic characteristics, date of potential exposure and onset of illness, nature, and type of exposure, clinical features, outcome, use of personal protective equipment (PPE), and personnel IPC training and were analyzed using descriptive statistics with Microsoft Excel. Results: The study included 21 HCWs, and 12 (57.14%) were doctors. The case fatality rate was 23%. Nearly two-thirds (62%) of the HCWs could describe a likely procedure leading to their exposure and infection. Among 13 HCWs, 85% had multiple blood and body fluids exposure, while 15% had needle stick injury or scalpel cut. About one-fifth of the participants had received some IPC training. Conclusion: Limited IPC adherence and inappropriate risk assessment were identified as factors leading to Lassa fever exposure and infection among HCWs. There is an urgent need to provide IPC training for all HCWs and to ensure an adequate supply of IPC materials to all healthcare facilities as part of emergency preparedness, especially in LF endemic areas.
- Open Access
- 30 June 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (26) , 2528-2530
Detection of Marburg Virus Disease in Guinea
On August 2, 2021, a 46-year-old man from Temessadou M’Boké, a village in Guéckédou prefecture in Guinea, died after hemorrhaging from several natural orifices. On August 3, an initial diagnosis of Marburg virus (MARV) infection was made after real-time reverse-transcriptase–polymerase-chain-reaction testing of a postmortem buccal sample obtained from the patient was performed and revealed a cycle-threshold value of 13.4 ( Figure 1A ). Field investigation teams were deployed, and the diagnostic finding was validated in two additional laboratories within a few days. In-country metagenomic next-generation sequencing allowed for full-length MARV genome recovery (99.3%), and phylogenetic analysis indicated that the new Guinea MARV strain that had been identified in the patient clustered with MARV strains isolated from bats in Sierra Leone and from humans in Angola (Fig. S1 and Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Close monitoring for a period of 21 days confirmed that all the patient’s contacts had remained asymptomatic, and no additional cases were detected.
- 30 June 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (26) , 2528-2530
Open AccessDetection of Marburg Virus Disease in Guinea
On August 2, 2021, a 46-year-old man from Temessadou M’Boké, a village in Guéckédou prefecture in Guinea, died after hemorrhaging from several natural orifices. On August 3, an initial diagnosis of Marburg virus (MARV) infection was made after real-time reverse-transcriptase–polymerase-chain-reaction testing of a postmortem buccal sample obtained from the patient was performed and revealed a cycle-threshold value of 13.4 ( Figure 1A ). Field investigation teams were deployed, and the diagnostic finding was validated in two additional laboratories within a few days. In-country metagenomic next-generation sequencing allowed for full-length MARV genome recovery (99.3%), and phylogenetic analysis indicated that the new Guinea MARV strain that had been identified in the patient clustered with MARV strains isolated from bats in Sierra Leone and from humans in Angola (Fig. S1 and Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Close monitoring for a period of 21 days confirmed that all the patient’s contacts had remained asymptomatic, and no additional cases were detected.